Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
197 |
Employees |
1 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-17 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
Cannagistics Inc
We are in the business of purchasing and selling colored diamonds and other
valuables.
We plan to manage a portfolio of rare colored diamonds that are selected for
price potential. Our officer and director, Kashif Khan, has established a worldwide
reputation as a purveyor of exquisite, extraordinary fine quality colored diamonds
that are sold at competitively reasonable prices. Through Mr. Khan’s reputation
and long standing close business ties to the diamond wholesale market, we plan
to have direct access to acquiring an unsurpassed collection of the highest
investment grade colored diamonds that are released on a wholesale basis to
auction houses, investors and jewelry wholesalers and retailers throughout Toronto
and Vancouver, Canada. We also intend to move our business into the United States,
and thereafter internationally as funds permit and if our growth sustains the
effort.
On October 26, 2016, however, we learned that it was not possible to obtain
an audit of Karrah that we were required to file with the SEC in connection
with the acquisition as a result of the nature of the company’s jewelry
inventory. Because we were unable to obtain an audit of Karrah, on October 28,
2016, we have restructured the entire transaction by entering into a Termination
and Restructure Agreement. First, we and Khan have mutually agreed to cancel
the Agreement to acquire the issue and outstanding shares of stock in Karrah.
Second, we agreed to purchase from Karrah its customer list in exchange for
a revised promissory note (the “New Note”). The New Note will be
in favor of Karrah (and not Khan), valued at $1,500,000 with interest at 6%
per annum, and will not be secured by the assets of Karrah. The customer list
has been invaluable in establishing our current colored diamond inventory. Third,
we have acquired some of the inventory from Karrah, and the value of the New
Note reflects that consideration as well. Finally, we will not be acquiring
the accounts receivable of Karrah so the AR Note will be terminated.
On December 5, 2016, we entered into an Asset Purchase Agreement (the “Purchase
Agreement”) with Cornerstone United Capital, LLC (“Cornerstone”).
Pursuant to the Purchase Agreement, we were to acquire from Cornerstone colored
diamonds with a wholesale value of $105,000,000 (the “Assets”).
In consideration for the Assets, we issued to Cornerstone and its nominees
a total of 214,000,000 shares of our common stock. In addition, Kashif Khan,
our prior officer and director, agreed to transfer his 16,000,000 shares of
common stock as part of the Purchase Agreement in exchange for 9,457,931 shares
of our Series B Preferred Stock.
Our long-term investment strategy includes:
• The creation of a world class portfolio of unique color diamonds with
high appreciation value, based on factors including closure of major producing
mines, world availability and cost per carat.
• To establish the company as an international branded investment colored
diamond and valuables merchant for the acquisitions of investment grade precious
stones that are acquired from individuals, mines and estates and sold through
private transactions to auction houses, investors and consumers interested in
obtaining such precious stones.
• To identify additional business opportunities where access to capital,
expert knowledge of rare and precious stones, and reputation are paramount to
success.
• To sell our valuables to wholesale or retail customers, including outfitted
and enhanced merchandise with our colored diamonds.
Some of the key factors that will help us expand our operations include:
• Timely accessing capital and debt financing sufficient to support increasing
short term and long term capital requirements and to expand opportunities and
respond to new business opportunities.
• Establishing proper risk and internal controls to assure that all inventory
assets are assessed correctly, properly secured and safeguarded to assure and
protect inventory.
• Maintaining the highest business integrity such that all sellers and
buyers can have comfort that they are being treated fairly and with the utmost
of respect, that there is transparency, and that there is a consistency in practices
across transactions.
• Expanding our visibility and access to sellers of colored diamonds and
other valuables such that we will be able to secure a sufficient volume of high
worth merchandise to support the buyer base and business overhead.
• Becoming more visible to diamond investors and speculators across Canada
and the United States.
• Developing a state of the art information system, inclusive of inventory
database, historical purchase and sale prices, number of days in inventory by
item and category, seller and buyer information and locations, demographics,
product interests, etc. that will give us an added competitive advantage and
improve our internal controls and information technology.
• Implementing a public relations and marketing program that will introduce
and reinforce our branding.
Company Address: 150 Motor Parkway Hauppauge 11788 NY
Company Phone Number: 787-8455 Stock Exchange / Ticker: PNIK
|
|
Customers Net Income grew by |
PNIK's Customers Net Profit Margin grew to |
|
3.19 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Chromadex Corporation
CDXC, also known as ChromaDex Corporation, recently achieved a break-even point with a moderate increase in revenue. In the most recent fiscal period, their revenue rose by 0.953% to $21.20 million compared to the corresponding quarter a year prior. While this may seem positive, it is crucial to understand how CDXC performed in relation to its competitors in the legal cannabis industry. Unfortunately, CDXC underperformed in comparison to its contemporaries, who reported a business advance of 4.20% from the same quarter a year ago. The previous quarter showed some improvement for CDXC, as their revenue increased by 8.725% from $19.50 million. Additionally, they achieved earnings of $0.114 million in the most recent fiscal period, a significant improvement compared to a net shortfall of $-1.418 million in the same quarter a year ago. Despite these positive aspects, CDXC's stockpiles have increased to $14.5 million, lower than the previous year's level of $14.7 million. Additionally, their accounts receivable has declined to $5.2 million, potentially indicating slowing demand.
|
Usana Health Sciences Inc
Despite a slight decrease in revenue during the October to December 2023 period, Usana Health Sciences Inc (USNA) managed to raise its earnings per share (EPS), showing significant growth in profit. The company reported a surge of 30.06% in profit per share to $0.87, while revenue fell by -2.722% to $221.76 million year on year. Comparing these results with the prior financial reporting period, Usana Health Sciences Inc demonstrated impressive growth. EPS soared from $0.59 per share, and revenue advanced by 4.195% from $212.84 million. This shows that the company is continuing to increase its profitability, even in the face of slightly lower revenue. Furthermore, Usana Health Sciences Inc highlighted its improving profit margins, with net margin rising to 7.56% and operating margin edging up to 10.92% during the October to December 2023 period. These figures indicate the company's ability to control costs and maximize its profitability.
|
Alterola Biotech Inc
Alterola Biotech Inc, a legal cannabis company, has recently released its financial report for the October to December 2023 reporting cycle. The shareholders have not anticipated any changes in revenue during this period. However, they have expressed concerns over the company's operating loss, which amounted to $-1.108947 million. To better understand the current state of the company, it is important to compare its performance with previous quarters. In the third quarter of 2023, Alterola Biotech Inc reported an operating loss of $0.540621 million. This indicates a significant increase in losses during the October to December 2023 reporting cycle.
|
Natural Alternatives International Inc
The financial results of Natural Alternatives International Inc. for the second quarter of 2024 paint a challenging picture for the company. The significant deficit per share, declining revenue, and net loss compared to the previous year all point towards a tough period for the company. One key highlight from the results is the decline in inventories and the increase in accounts receivable. The decrease in inventories could indicate lower expected demand for the company's products, while the rise in accounts receivable could suggest an increase in sales but delayed payments. These factors can have implications for the company's future performance and growth prospects.
|
Upexi Inc
Upexi Inc, a leading player in the legal cannabis sector, has recently posted disappointing financial results for the most recent fiscal period. Despite these challenges, there are signs of potential growth and improvement on the horizon. While the company reported a loss per share of $-0.12, a decline from the previous year, it is important to note that the legal cannabis sector as a whole has seen a 32.13% increase in revenue compared to the same period a year before. This indicates that there is still strong demand and opportunity in the industry, and Upexi Inc is well positioned to capitalize on this growth.
|
Per Share |
Current |
Earnings (TTM) |
-0.09 $ |
Revenues (TTM) |
-
|
Cash Flow (TTM) |
- |
Cash |
0 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.09 $
|
Revenues (TTM) |
- |
Cash Flow (TTM) |
- |
Cash |
0 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
|